Prodromal sensory neuropathy in Pink1
PTEN inducible kinase 1
Parkinson's disease
alpha-synuclein
glucosylceramides
innate immunity
mitochondrial respiration
pain
sensory loss
Journal
Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
28
03
2021
received:
02
11
2020
accepted:
02
05
2021
pubmed:
12
5
2021
medline:
5
3
2022
entrez:
11
5
2021
Statut:
ppublish
Résumé
Parkinson's disease (PD) is frequently associated with a prodromal sensory neuropathy manifesting with sensory loss and chronic pain. We have recently shown that PD-associated sensory neuropathy in patients is associated with high levels of glucosylceramides. Here, we assessed the underlying pathology and mechanisms in Pink1 We studied nociceptive and olfactory behaviour and the neuropathology of dorsal root ganglia (DRGs), including ultrastructure, mitochondrial respiration, transcriptomes, outgrowth and calcium currents of primary neurons, and tissue ceramides and sphingolipids before the onset of a PD-like disease that spontaneously develops in Pink1 Similar to PD patients, Pink1 The results suggest that pathological GlcCer contribute to prodromal sensory disease in PD mice via mitochondrial damage and calcium channel hyperexcitability. GlcCer-associated sensory neuron pathology might be amenable to GlcCer lowering therapeutic strategies.
Substances chimiques
Snca protein, mouse
0
alpha-Synuclein
0
Protein Kinases
EC 2.7.-
PTEN-induced putative kinase
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1060-1079Informations de copyright
© 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.
Références
Darweesh SK, Verlinden VJ, Stricker BH, Hofman A, Koudstaal PJ, Ikram MA. Trajectories of prediagnostic functioning in Parkinson's disease. Brain. 2017;140:429-441.
Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl. 1995;46:15-31.
Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 2015;14:57-64.
Rana AQ, Siddiqui I, Mosabbir A, et al. Association of pain, Parkinson's disease, and restless legs syndrome. J Neurol Sci. 2013;327:32-34.
Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013;20:16-34.
Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord. 2012;27:617-626.
Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology. 1976;26:423-429.
Klatt-Schreiner K, Valek L, Kang JS, et al. High glucosylceramides and low anandamide contribute to sensory loss and pain in Parkinson's disease. Mov Disord. 2020;35(10):1822-1833.
Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007;30:201-205.
Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 2004;62:2171-2175.
Yust-Katz S, Hershkovitz R, Gurevich T, Djaldetti R. Pain in extrapyramidal neurodegenerative diseases. Clin J Pain. 2017;33:635-639.
Leclair-Visonneau L, Magy L, Volteau C, et al. Heterogeneous pattern of autonomic dysfunction in Parkinson's disease. J Neurol. 2018;265:933-941.
Zambito Marsala S, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson's disease. J Neurol. 2011;258:627-633.
Kass-Iliyya L, Javed S, Gosal D, et al. Small fiber neuropathy in Parkinson's disease: a clinical, pathological and corneal confocal microscopy study. Parkinsonism Relat Disord. 2015;21:1454-1460.
Nolano M, Provitera V, Estraneo A, et al. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain. 2008;131:1903-1911.
Zis P, Grunewald RA, Chaudhuri RK, Hadjivassiliou M. Peripheral neuropathy in idiopathic Parkinson's disease: a systematic review. J Neurol Sci. 2017;378:204-209.
Nolano M, Provitera V, Manganelli F, et al. Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients. Neurology. 2017;89(8):776-784.
Strobel AV, Tankisi H, Finnerup NB, et al. Somatosensory function is impaired in patients with idiopathic REM sleep behaviour disorder. Sleep Med. 2018;42:83-89.
Silverdale MA, Kobylecki C, Kass-Iliyya L, et al. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. Parkinsonism Relat Disord. 2018;56:27-32.
Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord. 2015;30:229-237.
Rey NL, Steiner JA, Maroof N, et al. Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med. 2016;213:1759-1778.
Bernis ME, Babila JT, Breid S, Wusten KA, Wullner U, Tamguney G. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun. 2015;3:75.
Loria F, Vargas JY, Bousset L, et al. alpha-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathol. 2017;134:789-808.
Peelaerts W, Bousset L, Van der Perren A, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522:340-344.
Blanz J, Saftig P. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J Neurochem. 2016;139(Suppl 1):198-215.
Sliter DA, Martinez J, Hao L, et al. Parkin and PINK1 mitigate STING-induced inflammation. Nature. 2018;561:258-262.
Suzuki M, Sango K, Wada K, Nagai Y. Pathological role of lipid interaction with alpha-synuclein in Parkinson's disease. Neurochem Int. 2018;119:97-106.
Kim S, Yun SP, Lee S, et al. GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers. Proc Natl Acad Sci USA. 2018;115:798-803.
Zunke F, Moise AC, Belur NR, et al. Reversible conformational conversion of alpha-synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97:92-107.e10.
Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain. 2014;137:834-848.
Tayebi N, Parisiadou L, Berhe B, et al. Glucocerebrosidase haploinsufficiency in A53T alpha-synuclein mice impacts disease onset and course. Mol Genet Metab. 2017;122:198-208.
Suzuki M, Fujikake N, Takeuchi T, et al. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant alpha-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease. Hum Mol Genet. 2015;24:6675-6686.
Abul Khair SB, Dhanushkodi NR, Ardah MT, Chen W, Yang Y, Haque ME. Silencing of glucocerebrosidase gene in drosophila enhances the aggregation of Parkinson's disease associated alpha-synuclein mutant A53T and affects locomotor activity. Front Neurosci. 2018;12:81.
Migdalska-Richards A, Wegrzynowicz M, Rusconi R, et al. The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. Brain. 2017;140:2706-2721.
Do J, McKinney C, Sharma P, Sidransky E. Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019;14:36.
Alcalay RN, Levy OA, Waters CC, et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015;138:2648-2658.
Murphy KE, Halliday GM. Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy. 2014;10:1350-1351.
Robak LA, Jansen IE, van Rooij J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain. 2017;140:3191-3203.
Schulze H, Sandhoff K. Lysosomal lipid storage diseases. Cold Spring Harb Perspect Biol. 2011;3.
Ishibashi Y, Kohyama-Koganeya A, Hirabayashi Y. New insights on glucosylated lipids: metabolism and functions. Biochim Biophys Acta. 2013;1831:1475-1485.
Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O. Emerging analgesic drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2012;17:157-171.
Sophie M, Ford B. Management of pain in Parkinson's disease. CNS Drugs. 2012;26:937-948.
Valek L, Auburger G, Tegeder I. Sensory neuropathy and nociception in rodent models of Parkinson's disease. Dis Model Mech. 2019;12:dmm039396.
Gispert S, Brehm N, Weil J, et al. Potentiation of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression. Hum Mol Genet. 2015;24:1061-1076.
Touska F, Winter Z, Mueller A, Vlachova V, Larsen J, Zimmermann K. Comprehensive thermal preference phenotyping in mice using a novel automated circular gradient assay. Temperature. 2016;3:77-91.
Valek L, Haussler A, Drose S, Eaton P, Schroder K, Tegeder I. Redox-guided axonal regrowth requires cyclic GMP dependent protein kinase 1: implication for neuropathic pain. Redox Biol. 2017;11:176-191.
Schmidtko A, Luo C, Gao W, Geisslinger G, Kuner R, Tegeder I. Genetic deletion of synapsin II reduces neuropathic pain due to reduced glutamate but increased GABA in the spinal cord dorsal horn. Pain. 2008;139:632-643.
Tegeder I, Costigan M, Griffin RS, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med. 2006;12:1269-1277.
Fischer C, Endle H, Schumann L, et al. Prevention of age-associated neuronal hyperexcitability with improved learning and attention upon knockout or antagonism of LPAR2. Cell Mol Life Sci. 2021;78(3):1029-1050.
Brunkhorst-Kanaan N, Klatt-Schreiner K, Hackel J, et al. Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder. Metabolism. 2019;95:65-76.
Luo M, Fee MS, Katz LC. Encoding pheromonal signals in the accessory olfactory bulb of behaving mice. Science. 2003;299:1196-1201.
Schömel N, Gruber L, Alexopoulos SJ, et al. UGCG overexpression leads to increased glycolysis and increased oxidative phosphorylation of breast cancer cells. Sci Rep. 2020;10:8182.
Altmann C, Hardt S, Fischer C, et al. Progranulin overexpression in sensory neurons attenuates neuropathic pain in mice: role of autophagy. Neurobiol Dis. 2016;96:294-311.
Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, Lubbert H. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum Mol Genet. 2007;16:2377-2393.
Manczak M, Mao P, Calkins MJ, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis. 2010;20(Suppl 2):S609-S631.
Gaudioso A, Garcia-Rozas P, Casarejos MJ, Pastor O, Rodriguez-Navarro JA. Lipidomic alterations in the mitochondria of aged Parkin null mice relevant to autophagy. Front Neurosci. 2019;13:329.
Li H, Ham A, Ma TC, et al. Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy. 2019;15:113-130.
Plotegher N, Perocheau D, Ferrazza R, et al. Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload. Cell Death Differ. 2020;27(5):1588-1603.
Wei X, He S, Wang Z, et al. Fibroblast growth factor 1attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of parkinson's disease. Am J Transl Res. 2014;6:664-677.
de Yebenes JG, Pernaute RS, Garrido JM, et al. Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys. Parkinsonism Relat Disord. 1998;4:147-158.
Oellig C, Pirvola U, Taylor L, Elde R, Hökfelt T, Pettersson RF. Acidic FGF and FGF receptors are specifically expressed in neurons of developing and adult rat dorsal root ganglia. Eur J Neurosci. 1995;7:863-874.
Mohiuddin L, Fernyhough P, Tomlinson DR. Acidic fibroblast growth factor enhances neurite outgrowth and stimulates expression of GAP-43 and T alpha 1 alpha-tubulin in cultured neurones from adult rat dorsal root ganglia. Neurosci Lett. 1996;215:111-114.
Glueckert R, Bitsche M, Miller JM, et al. Deafferentation-associated changes in afferent and efferent processes in the guinea pig cochlea and afferent regeneration with chronic intrascalar brain-derived neurotrophic factor and acidic fibroblast growth factor. J Comp Neurol. 2008;507:1602-1621.
Luo L, Koutnouyan H, Baird A, Ryan AF. Acidic and basic FGF mRNA expression in the adult and developing rat cochlea. Hear Res. 1993;69:182-193.
Bugra K, Olivier L, Jacquemin E, Laurent M, Courtois Y, Hicks D. Acidic fibroblast growth factor is expressed abundantly by photoreceptors within the developing and mature rat retina. Eur J Neurosci. 1994;6:1062.
Torres-Odio S, Key J, Hoepken HH, et al. Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation. J Neuroinflammation. 2017;14:154.
Liss B, Haeckel O, Wildmann J, Miki T, Seino S, Roeper J. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat Neurosci. 2005;8:1742-1751.
Hardie RC. TRP channels and lipids: from Drosophila to mammalian physiology. J Physiol. 2007;578:9-24.
Prescott ED, Julius D. A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science. 2003;300:1284-1288.
Qin F. Regulation of TRP ion channels by phosphatidylinositol-4,5-bisphosphate. Handb Exp Pharmacol. 2007;509-525. https://doi.org/10.1007/978-3-540-34891-7_30.
Brumovsky P, Villar MJ, Hokfelt T. Tyrosine hydroxylase is expressed in a subpopulation of small dorsal root ganglion neurons in the adult mouse. Exp Neurol. 2006;200:153-165.
Lin CH, Chao CC, Wu SW, et al. Pathophysiology of small-fiber sensory system in parkinson's disease: skin innervation and contact heat evoked potential. Medicine. 2016;95:e3058.
Numazaki M, Tominaga M. Nociception and TRP channels. Curr Drug Targets CNS Neurol Disord. 2004;3:479-485.
Tominaga M, Caterina MJ. Thermosensation and pain. J Neurobiol. 2004;61:3-12.
Brenneis C, Kistner K, Puopolo M, et al. Phenotyping the function of TRPV1-expressing sensory neurons by targeted axonal silencing. J Neurosci. 2013;33:315-326.
Li L, Rutlin M, Abraira VE, et al. The functional organization of cutaneous low-threshold mechanosensory neurons. Cell. 2011;147:1615-1627.
Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131:1912-1925.
Kilpatrick BS, Magalhaes J, Beavan MS, et al. Endoplasmic reticulum and lysosomal Ca(2)(+) stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts. Cell Calcium. 2016;59:12-20.
Magalhaes J, Gegg ME, Migdalska-Richards A, Doherty MK, Whitfield PD, Schapira AH. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol Genet. 2016;25:3432-3445.
Biegstraaten M, Mengel E, Marodi L, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain. 2010;133:2909-2919.
Murugesan V, Chuang WL, Liu J, et al. Glucosylsphingosine is a key Biomarker of Gaucher disease. Am J Hematol. 2016;91:1082-1089.
Rolfs A, Giese AK, Grittner U, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a Non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One. 2013;8:e79732.
Strasberg P. Cerebrosides and psychosine disrupt mitochondrial functions. Biochem Cell Biol. 1986;64:485-489.
Igisu H, Nakamura M. Inhibition of cytochrome c oxidase by psychosine (galactosylsphingosine). Biochem Biophys Res Commun. 1986;137:323-327.
Hayashida K, Oyanagi S, Mizutani Y, Yokochi M. An early cytoplasmic change before Lewy body maturation: an ultrastructural study of the substantia nigra from an autopsy case of juvenile parkinsonism. Acta Neuropathol. 1993;85:445-448.
Trimmer PA, Swerdlow RH, Parks JK, et al. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol. 2000;162:37-50.
Roy S, Wolman L. Ultrastructural observations in Parkinsonism. J Pathol. 1969;99:39-44.
Chen Y, Dorn GW 2nd. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science. 2013;340:471-475.
Geisler S, Holmstrom KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010;12:119-131.
Kawajiri S, Saiki S, Sato S, et al. PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. FEBS Lett. 2010;584:1073-1079.
Zhao Y, Ren J, Padilla-Parra S, Fry EE, Stuart DI. Lysosome sorting of β-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor. Nat Commun. 2014;5:4321.
Reczek D, Schwake M, Schröder J, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell. 2007;131:770-783.
Tegeder I, Kögel D. When lipid homeostasis runs havoc: lipotoxicity links lysosomal dysfunction to autophagy. Matrix Biol. 2020. https://doi.org/10.1016/j.matbio.2020.11.005.
Wang W, Zhang X, Gao Q, et al. TRPML1: an ion channel in the lysosome Drosophila TRPML forms PI(3,5)P2-activated cation channels in both endolysosomes and plasma membrane. Handb Exp Pharmacol. 2014;222:631-645.
Shen D, Wang X, Li X, et al. Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. Nat Commun. 2012;3:731.
Gómez NM, Lu W, Lim JC, et al. Robust lysosomal calcium signaling through channel TRPML1 is impaired by lysosomal lipid accumulation. FASEB J. 2018;32:782-794.
Bhave G, Hu H-J, Glauner KS, et al. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci USA. 2003;100(21):12480-12485.
Van Buren JJ, Bhat S, Rotello R, Pauza ME, Premkumar LS. Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol Pain. 2005;1:17.
Susankova K, Tousova K, Vyklicky L, Teisinger J, Vlachova V. Reducing and oxidizing agents sensitize heat-activated vanilloid receptor (TRPV1) current. Mol Pharmacol. 2006;70:383-394.
Rosenbaum T, Gordon-Shaag A, Munari M, Gordon SE. Ca2+/calmodulin modulates TRPV1 activation by capsaicin. J Gen Physiol. 2004;123:53-62.
Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J. 2005;24:4211-4223.
Yao J, Qin F. Interaction with phosphoinositides confers adaptation onto the TRPV1 pain receptor. PLoS Biol. 2009;7:e1000046.
Zimmer B, Angioni C, Osthues T, et al. The oxidized linoleic acid metabolite 12,13-DiHOME mediates thermal hyperalgesia during inflammatory pain. Biochim Biophys Acta. 2018;1863:669-678.
Sisignano M, Angioni C, Park CK, et al. Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. Proc Natl Acad Sci USA. 2016;113(44):12544-12549.
Batta G, Soltesz L, Kovacs T, et al. Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease. Sci Rep. 2018;8:157.
West AP, Khoury-Hanold W, Staron M, et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520:553-557.
Mathur V, Burai R, Vest RT, et al. Activation of the STING-dependent type I interferon response reduces microglial reactivity and neuroinflammation. Neuron. 2017;96:1290-302.e6.